Hong Kong – 7 October 2026 – CStone Pharmaceuticals (CStone Pharma-B) reported a marginal expansion of its share base for September 2026, according to the company’s Monthly Return filed with Hong Kong Exchanges and Clearing Limited (HKEX).

The authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to USD 0.20 million.

Issued Share Movement • New shares issued: 7,381 ordinary shares, all arising from exercises under the Post-IPO Employee Share Option Plan (adopted 30 January 2019, amended 7 March 2023). • Month-end issued shares (excluding treasury): 1,596.33 million, up from 1,596.32 million in August. • Percentage dilution: approximately 0.0005 %. • Total proceeds from option exercise: HKD 0.02 million.

Options in Force • Pre-IPO Incentivization Plan: 1.04 million options outstanding; no exercises during the month. • Post-IPO Employee Share Option Plan: 104.77 million options outstanding post-exercise; up to 44.94 million additional shares remain issuable, with 22.03 million shares available for future grants.

Treasury Shares & Public Float • No treasury shares were held, issued, or cancelled during the month. • The company confirmed compliance with HKEX’s minimum 25 % public-float requirement as at 30 September 2026.

No warrants, convertible securities, or other share-linked agreements were reported for the period.